Menin in normal and malignant megakaryopoiesis
Cancer Cell · 2026-08 · 44 (8) · 1544-1546
DOI: 10.1016/j.ccell.2026.06.012 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2026-08. Verfasst von Justin C Wheat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Thrombopoiesis, Megakaryocytes, Myeloproliferative Disorders. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Severe thrombocytopenia is a known complication of menin inhibitor therapy; however, the mechanism underlying this effect is unknown. In this issue of Cancer Cell, Wen et al. demonstrate that menin is a key component of normal megakaryopoiesis and establish menin as a therapeutic vulnerability in myeloproliferative neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: cais1@mskcc.org.
Zitieren
APA
Wheat, J. C., & Cai, S. F. (2026). Menin in normal and malignant megakaryopoiesis. Cancer Cell, 44(8), 1544-1546. https://doi.org/10.1016/j.ccell.2026.06.012
Vancouver
Wheat JC, Cai SF. Menin in normal and malignant megakaryopoiesis. Cancer Cell. 2026;44(8):1544-1546. doi:10.1016/j.ccell.2026.06.012
BibTeX
@article{Wheat2026,
author = {Wheat, Justin C and Cai, Sheng F},
title = {Menin in normal and malignant megakaryopoiesis},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {8},
pages = {1544--1546},
doi = {10.1016/j.ccell.2026.06.012}
}
EUVIMED